The import of insulin in dosage forms to the UK demonstrates a steady growth from 2024 to 2028, with values increasing from $494.92 million in 2024 to $509.68 million in 2028. This growth is consistent with year-on-year variations slightly over 1% annually. In 2023, the actual import value was slightly below the 2024 forecast, indicating an upward trend beginning in 2024. The compound annual growth rate (CAGR) over this five-year period is moderate, reflecting stable market conditions.

Future trends to watch:

Potential market disruptions due to changes in healthcare policies or trade agreements, impacting import levels.
Technological advancements in diabetes treatment that might influence insulin demand.
Demographic shifts towards an aging population could contribute to increased insulin consumption.